Ciprofloxacin
Invasive Bacterial Infection
Hospital Universitari Vall d'Hebron Research InstituteSmall moleculePhase 4 / ApprovedActive
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 81/ 100
Competitive context
8 Active assets in the Invasive Bacterial Infection cohort.
Same molecule, other indications
Ciprofloxacin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →